This study is for patients that have been been newly diagnosed with advanced (Stage III or IV) classical Hodgkin lymphoma (HL) (a cancer of the lymph nodes) and have not received any treatment for the disease. In this study, patients will receive one of two regimens (or treatment plans), either a regimen that includes an investigational drug called brentuximab vedotin (also known as ADCETRIS®) or the current standard of care treatement (this regimen/group is referred to as Arm B). The main purpose of this study is to measure how well treatment in Arm A works compared to treatment in Arm B for Hodgkin lymphoma. This study is split up into 4 different periods: Screening, Treatment, End of Treatment, and Post-Treatment Follow up. Depending upon how patients respond, their treatment period (the portion of the study where you will continue to receive study treatment) can last approximately 6 months. Patients' study participation, including post-treatment follow-up, can last up to 7 years, depending on when they start the study.
The purpose of this study is to find out whether vemurafenib can help prevent or delay the return of melanoma that is at a high risk of returning (Stage IIC, IIIA, IIIB or IIIC) after it has been removed surgically. The study will also assess whether the drug causes side effects in patients.
Vemurafenib was recently approved in the United States for the treatment of patients with metastatic melanoma. Vemurafenib remains an investigational drug being studied by Roche.
This study is for patients with multiple ipsilateral breast cancers (MIBC). The purpose of this research study is to see if removing only the tissues from the 2 or 3 cancers in the patient's breast (breast conservation surgery) in combination with radiation to the breast, instead of removing the patient's entire breast (mastectomy) is safe in keeping the patient's cancer from coming back in the patient's breast. Patients will be asked to visit the study doctor for follow-up exams for up to 5 years after patients have completed WBI.
The primary objective is to determine the MTD and safety profile of SG2000 in adult subjects with AML and CLL.
The secondary objectives are as follows to characterize the PK profile of SG2000 in subjects with CLL and AML; to describe the preliminary efficacy profile of SG2000 in subjects with CLL and AML and to investigate the following clinical and laboratory parameters as potential predictors of VLS: orthostatic blood pressure, albumin levels, weight changes, edema, and pulmonary findings.
This study is for patients that have been diagnosed with lung cancer who cannot have surgery because of the location of or advanced stage of the cancer or other serious health problems such as emphysema, diabetes, or heart disease. The purpose of this study is to find out if more intense (higher dose) radiation treatment based on the FDG-PET/CT imaging improves treatment of this cancer with the same possible damage to healthy lung tissue compared to treatment with standard radiation therapy. The higher dose radiation is aimed at the tumor. Patients will be randomized into one of two groups; Group A will receive standard radiation treatment once daily, 5 days a week for 5 weeks. They will also will receive chemotherapy (paclitaxel and carboplatin), once a week for 6 weeks. Group B will receive radiation treatment once daily, 5 days a week for 3-4 weeks. This radiation treatment will be a higher dose per day than standard radiation. Patients will also receive chemotherapy (paclitaxel and carboplatin), once a week for 6 weeks. Both groups will receive Paclitaxel and carboplatin are given by vein before radiation therapy. Both groups will also receive paclitaxel and carboplatin by vein every 21 days X 3, a total of 3 cycles of chemotherapy four to six weeks after radiation treatment is completed.
This study is for patients with advanced renal cell carcinoma. This is a Phase II study for the experimental treatment of kidney cancer. The drugs to be examined in this study are a combination of ixabepilone and bevacizumab. The purpose of this phase II study is to determine whether the combination of ixabepilone administered for five consecutive days and bevacizumab administered on one day, both repeated every three weeks, is effective in the treatment of kidney cancer.
This study is for subjects who have been treated with tivozanib hydrochloride (AV-951) on another AVEO Pharmaceuticals, Inc. protocol for their cancer and would like to continue treatment. At MUSC, this study is for those subjects previously enrolled on AVEO study AV-951-12-205 (CTO 101763) who would like to continue treatment with tivozanib.
This study will involve the investigational drug, tivozanib hydrochloride. Tivozanib hydrochloride has not yet been approved for sale by the United States Food and Drug Administration (FDA), or any other country’s regulatory agency. Participation in this study may last as long as subjects tolerate treatment and receive benefit. The protocol will be open to any subjects who have participated on another tivozanib hydrochloride protocol and are tolerating treatment and receiving benefit. This study may be stopped after tivozanib hydrochloride is commercially available.
This is a rollover study. “Rollover” means that subjects and their study doctor will continue with the protocol treatment from their previous AVEO Pharmaceuticals, Inc. protocol. (AV-951-12-205). The main goal of this study is to allow continued access to tivozanib hydrochloride for subjects who have participated on a previous tivozanib hydrochloride protocol and are receiving benefit. The study team will also be assessing long-term safety and tolerability of tivozanib hydrochloride alone or in combination (if subjects participated in a combination protocol). An additional goal is to see if tivozanib hydrochloride alone or in combination (if subjects participated in a combination protocol) can slow the growth of cancer over time.
The purpose of this study is to look at the type of HPV linked with cervical cancer in european american women compared to african american women. At the time of pelvic examination as part of usual care, 2 extra Pap test samples will be collected. Patients may also donate a sample of cervical tumor tissue, a sample of blood and/or a sample of urine for the study.
The primary purpose of the this study is to evaluate the quality of life of lactating mothers using an all-natural, organic, herbal tea that is currently on the market and has been commercially available for over thirty years in the United States. Compensation is available. Please call the study coordinator for more details.